Clinical trials in Monza – page 103

2 831 clinical trials in Monza, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in ItalyStudi-Clinici.it

Monza at a glance

2 831

clinical trials

Research sites1

Quick filters

2 831 trials in Monza

Open in trial search

Heart disease congenital

Not yet recruiting

Safety and pharmacodynamics of cangrelor tetrasodium in paediatric patients with congenital heart disease undergoing percutaneous vascular procedures

Registered drugNo placebo

Safety and pharmacodynamics of cangrelor tetrasodium in paediatric patients with congenital heart disease undergoing percutaneous vascular procedures

Registered drugNo placebo

Italy

Participants:0–17 years
Substances:Cangrelor Tetrasodium
Sponsor:Chiesi Farmaceutici S.p.A.

Contact Research Centre

Cystic fibrosis

Not yet recruiting

Safety and Efficacy of VX-828, Deutivacaftor, and Tezacaftor in Adults with Cystic Fibrosis

Registered drug

Safety and Efficacy of VX-828, Deutivacaftor, and Tezacaftor in Adults with Cystic Fibrosis

Registered drug

Italy

Participants:18–64 years · 65+ years
Sponsor:Vertex Pharmaceuticals Inc.

Contact Research Centre

Primary immunodeficiency syndrome

Not yet recruiting

Autologous CD4+ T-Cell Gene Therapy for X-linked Hyper-IgM Syndrome Type 1 in Patients with X-linked Hyper-IgM Syndrome Type 1

Registered drugNo placebo

Autologous CD4+ T-Cell Gene Therapy for X-linked Hyper-IgM Syndrome Type 1 in Patients with X-linked Hyper-IgM Syndrome Type 1

Registered drugNo placebo

Italy

Participants:0–17 years · 18–64 years · 65+ years
Substances:Telethon_028
Sponsor:Fondazione Telethon Ets

Contact Research Centre

Transitional cell carcinoma metastatic

Not yet recruiting

Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma After Second-Line Platinum-Based Chemotherapy

Registered drugNo placebo

Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma After Second-Line Platinum-Based Chemotherapy

Registered drugNo placebo

Italy

Participants:18–64 years
Substances:Avelumab
Sponsor:G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica

Contact Research Centre

Hepatocellular carcinoma+5

Not yet recruiting

DB-1311 in Combination with BNT327 or DB-1305 for Patients with Advanced or Metastatic Solid Tumors

InvestigationalNo placebo

DB-1311 in Combination with BNT327 or DB-1305 for Patients with Advanced or Metastatic Solid Tumors

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:BNT324
Sponsor:Dualitybio Inc.

Contact Research Centre

Neoplasm+2

Not yet recruiting

REGN10597 Alone or with Cemiplimab in Adults with Advanced Solid Tumours, Melanoma, or Clear-Cell Renal-Cell Carcinoma

Registered drugNo placebo

REGN10597 Alone or with Cemiplimab in Adults with Advanced Solid Tumours, Melanoma, or Clear-Cell Renal-Cell Carcinoma

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Cemiplimab
Sponsor:Regeneron Pharmaceuticals Inc.

Contact Research Centre

Type 2 diabetes mellitus+2

Not yet recruiting

A Study of Zenagamtide in Adults With Overweight or Obesity and Type 2 Diabetes

Investigational

A Study of Zenagamtide in Adults With Overweight or Obesity and Type 2 Diabetes

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Zenagamtide
Sponsor:Novo Nordisk A/S

Contact Research Centre

B precursor type acute leukaemia

Not yet recruiting

Study of asciminib, dexamethasone, blinatumomab, and vincristine sulfate in children and young adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia

Registered drugNo placebo

Study of asciminib, dexamethasone, blinatumomab, and vincristine sulfate in children and young adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia

Registered drugNo placebo

Italy

Participants:0–17 years · 18–64 years
Substances:Blinatumomab
Sponsor:Novartis Pharma AG

Contact Research Centre

Idiopathic pulmonary fibrosis

Not yet recruiting

A study to evaluate the safety and effectiveness of zampilimab in people with idiopathic pulmonary fibrosis

Investigational

A study to evaluate the safety and effectiveness of zampilimab in people with idiopathic pulmonary fibrosis

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Zampilimab
Sponsor:Chiesi Farmaceutici S.p.A.

Contact Research Centre

Deep vein thrombosis+1

Not yet recruiting

A study to evaluate the use of colchicine to reduce inflammation in patients with deep vein thrombosis.

Registered drug

A study to evaluate the use of colchicine to reduce inflammation in patients with deep vein thrombosis.

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Colchicine
Sponsor:Universita' Degli Studi G. D'Annunzio Di Chieti

Contact Research Centre

Hereditary haemochromatosis

Not yet recruiting

A study to evaluate the effectiveness and safety of vamifeport in adults with hereditary hemochromatosis

Investigational

A study to evaluate the effectiveness and safety of vamifeport in adults with hereditary hemochromatosis

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Vamifeport trihydrochloride
Sponsor:CSL Behring LLC

Contact Research Centre

Type 1 diabetes mellitus

Not yet recruiting

Study of the efficacy and safety of ladarixin and rabbit anti-human thymocyte immunoglobulin in adolescents and adults with new-onset type 1 diabetes

Registered drug

Study of the efficacy and safety of ladarixin and rabbit anti-human thymocyte immunoglobulin in adolescents and adults with new-onset type 1 diabetes

Registered drug

Italy

Participants:0–17 years · 18–64 years
Substances:Ladarixin
Sponsor:Ospedale San Raffaele S.r.l.

Contact Research Centre

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Monza

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on lung cancer treatments and novel approaches for lymphoma management. Studies include targeted therapies and immunotherapy combinations.

NSCLC Treatment Studies
Lymphoma Therapy Innovations
Breast Cancer Research

Advanced investigations into personalized treatment approaches for various cancer types using targeted therapies and immunological interventions.

02 Autoimmune Conditions

Research focusing on psoriatic arthritis and multiple sclerosis, evaluating novel biological treatments and their effectiveness in managing disease progression.

Inflammatory Disease Studies
Biomarker Research
Treatment Response Evaluation

Comprehensive studies examining new therapeutic approaches for chronic autoimmune conditions.

03 Infectious Diseases

Vaccine development studies targeting Herpes Zoster and Cytomegalovirus, focusing on prevention and immune response in different age groups.

Vaccine Efficacy Studies
Long-term Immunity Research
Viral Prevention Strategies

Advanced clinical trials evaluating new vaccination approaches and therapeutic strategies.

04 Cardiovascular Studies

Innovative research on heart failure prevention and pulmonary arterial hypertension, testing new therapeutic combinations and treatment approaches.

Preventive Cardiology
Hypertension Management
Drug Combination Studies

Investigation of novel therapeutic strategies for cardiovascular disease management and prevention.

Back to Italy All countries